High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study)

Higher plasma fibroblast growth factor 21 (FGF21) levels predict incident cardiovascular events in type 2 diabetes patients. However, whether FGF21 levels predict cardiovascular events in statin-treated patients in the general population is unknown. We investigated whether FGF21 levels predict major cardiovascular event (MCVE) in the Treating to New Targets (TNT) trial participants.

Source: Metabolism - Clinical and Experimental - November 16, 2018 Category: Biomedical Science Authors: Kwok Leung Ong, Nicholas Hui, Andrzej S. Januszewski, Nadeem O. Kaakoush, Aimin Xu, Rana Fayyad, David A. DeMicco, Alicia J. Jenkins, Anthony C. Keech, David D. Waters, Philip J. Barter, Kerry-Anne Rye Source Type: research